Checkpoint blocker plus chemo shows impact in lung cancer

7 May 2020
innovent_large

A multi-year collaboration between China’s Innovent Biologics (HKEX: 01801) and USA-based Eli Lilly (NYSE: LLY) is bearing fruit, with positive Phase III data in lung cancer.

The ORIENT-12 trial is studying the checkpoint blocker Tyvyt (sintilimab), in combination with the chemotherapeutic Gemzar (gemcitabine) and platinum chemotherapy, in first-line advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).

The study met the primary endpoint of progression-free survival (PFS), showing a statistically-significant improvement, compared to placebo plus Gemzar and platinum chemo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology